Fresenius Kabi announced that it entered into a U.S. distribution agreement with Corvida Medical for the HALO closed system drug-transfer device (CSTD).
Under the distribution agreement, Lake Zurich, Ill.-based Fresenius Kabi will be the exclusive U.S. distributor for the HALO CSTD, an airtight and leak-proof CSTD designed to prohibit the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, according to a news release.
Common challenges such as individual and environmental exposure to drug vapor, aerosols and droplets can be minimized during the compounding and administration of hazardous drugs like in chemotherapy through the use of the HALO system.
Financial terms of the distribution agreement were not disclosed. The companies said the deal could be expanded to other territories in the future.
“Fresenius Kabi is committed to offering solutions that provide the safe preparation and delivery of medications across the continuum of care,” Fresenius Kabi USA president & CEO John Ducker said in the release. “CSTDs play a critical role in protecting health care professionals from the risks of exposure to hazardous drugs during the preparation in the pharmacy and during patient administration by nurses. The combination of Fresenius Kabi freeflex/freeflex+ IV solution containers, oncology medicines and Corvida Medical’s HALO CSTD allows Fresenius Kabi to provide customers a broad range of products to assist with their oncology needs.”
“We believe Fresenius Kabi is a great partner for the HALO closed system drug-transfer device,” added Corvida Medical CEO Mitch Moeller. “Their reputation for quality and patient focus along with their commercial infrastructure, distribution experience, customer relationships and extensive product portfolio will help our efforts to make HALO a leading CSTD option for U.S. customers. We are pleased that Fresenius Kabi recognized the design benefits, innovation and quality of the HALO product portfolio.”
